fiercebiotech.com
Moderna and Merck's Personalized mRNA Cancer Vaccine Shows Success in Phase 3 Melanoma Trial
A personalized mRNA cancer vaccine, developed by Moderna and Merck & Co., has shown positive results in a Phase 3 study for high-risk melanoma patients. The vaccine, customized to each patient's tumor